Antineoplastic Agents

All Drugs and Chemicals

Anti-Infective Agents

Anti-Inflammatory Agents

Durvalumab

Avdoralimab

Antineoplastic Agents, Immunological

Antiviral Agents

IPH5401 at different doses and schedule + Durvalumab

IPH5401 at recommended dose and schedule + Durvalumab in NSCLC anti-PD-(L)1 pretreated patients

IPH5401 at recommended dose and schedule + Durvalumab in HCC anti-PD-(L)1 naive patients

IPH5401 at recommended dose and schedule + Durvalumab in HCC anti-PD-(L)1 pretreated patients

IPH5401 and Durvalumab

This is a multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, antitumor activity of IPH5401 (anti C5aR) in combination with Durvalumab (MEDI4736) in Adult Subjects with selected advanced solid tumors.

IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors

A Phase I Study of the Anti-C5aR, IPH5401, in Combination With the Anti-PD-L1, Durvalumab, in Patients With Selected Advanced Solid Tumors

To assess the occurrence of Drug Limited Toxicities (DLTs)

Rate of patients in complete or partial response according to RECIST 1.1

duration between the complete or partial response and the first documented progression

time between the start of treatment and the first documented progression or death

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors	NCT03665129	Advanced Solid ...	IPH5401 and Dur...	18 Years -	Innate Pharma
IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors	NCT03665129	Advanced Solid ...	IPH5401 and Dur...	18 Years -	Innate Pharma

Spots Global Cancer Trial Database for iph5401 and durvalumab